What Voltaren Gel is and how side effects can occur
Voltaren Gel contains diclofenac sodium 1%, a topical nonsteroidal anti-inflammatory drug (NSAID) approved for the relief of osteoarthritis pain in joints close to the skin's surface, such as the knees, ankles, feet, hands, wrists, and elbows. Consumers often encounter this medication under different names: “Voltaren Gel” refers to the prescription brand, while “Voltaren Arthritis Pain” is the over-the-counter version. These products are identical in strength, formula, and active ingredient.
When applied to the skin, diclofenac sodium absorbs locally to reduce inflammation and pain at the joint site. Because it is applied topically rather than swallowed, the amount of medication that enters the bloodstream is significantly lower than with oral NSAID tablets. Systemic exposure from Voltaren Gel is approximately 6% of the exposure provided by oral diclofenac sodium, representing a 94% reduction in systemic availability.
Despite this substantially lower systemic absorption, serious side effects associated with oral NSAIDs still apply to the topical form. While application-site reactions are the most frequent issue, the small amount of drug that enters circulation is sufficient to trigger systemic risks. Users must understand that Voltaren Gel is not risk-free simply because it is applied externally. The medication carries FDA black box warnings for serious cardiovascular and gastrointestinal events, meaning that even low-level systemic exposure can pose significant health hazards in susceptible individuals.
Common side effects at the application site
The most frequently reported side effects of Voltaren Gel occur directly where the gel is applied to the skin. In clinical trials, application site reactions occurred in 7% of patients using Voltaren Gel, compared to just 2% of those using a placebo. Among these reactions, application site dermatitis-characterized by redness, rash, or inflammation-was the most common, affecting approximately 4% of users versus less than 1% of placebo recipients.
The specific types of skin reactions can vary and include itching (pruritus), tingling (paresthesia), dryness, peeling skin, small bumps (papules), and fluid-filled blisters (vesicles). While many users experience only mild irritation that resolves with continued use or by switching application sites, these reactions can be bothersome. In long-term studies, application site dermatitis occurred in up to 11% of patients and was cited as the primary reason for discontinuing the medication in 6% of cases.
Most local skin reactions are not dangerous but may require stopping the medication to allow the skin to heal. If irritation persists, worsens, or involves a large area of the body, users should discontinue use and consult a healthcare provider. Distinguish these common, manageable local irritations from the serious systemic warnings addressed in subsequent sections, though any unexpected or severe skin change warrants medical evaluation.
Systemic side effects beyond the skin
Although Voltaren Gel delivers the majority of its effect locally, a small percentage of the active ingredient enters the bloodstream, which can lead to systemic side effects similar to those seen with oral NSAIDs, albeit at a lower frequency. These less common systemic reactions affect organs and systems throughout the body rather than just the application site.
Gastrointestinal symptoms are among the more frequently reported systemic effects, including heartburn, gas, stomach pain, nausea, vomiting, diarrhea, and constipation. Some users may also experience neurological or general physical symptoms such as headache, dizziness, drowsiness, stuffy nose, increased sweating, or elevated blood pressure. While these effects are generally milder and less common with topical application than with oral tablets, they indicate that the medication is affecting the body systemically.
These systemic symptoms should be monitored closely, particularly if they persist or interfere with daily activities. These general side effects are distinct from the severe, life-threatening risks outlined in the FDA black box warnings for gastrointestinal bleeding and cardiovascular events. Their presence confirms that Voltaren Gel is not entirely free of systemic physiological impact. If mild systemic symptoms become persistent, users should consult a doctor to determine whether continuing the medication is appropriate or if an alternative treatment is needed.
Serious cardiovascular and stroke warnings
Voltaren Gel carries an FDA black box warning-the agency's strictest safety alert-regarding the risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. Although systemic exposure to diclofenac is much lower with the gel than with oral forms, the risk of these events still exists and may increase with the duration of use and higher doses.
Patients with existing cardiovascular disease or risk factors such as high blood pressure, high cholesterol, diabetes, or a history of smoking are at greater risk for these events. Cardiovascular thrombotic events can occur at any time during NSAID use and without prior warning symptoms. Even individuals with no known heart disease or risk factors can experience a heart attack or stroke while using topical diclofenac.
Voltaren Gel is strictly contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery due to this elevated risk. Users must be aware of the specific warning signs that indicate a potential cardiovascular emergency, including chest pain that spreads to the jaw or shoulder, sudden numbness or weakness on one side of the body, slurred speech, sudden shortness of breath, and weakness in a specific part or side of the body. If any of these symptoms occur, emergency medical care should be sought immediately.
Gastrointestinal risks including bleeding and ulcers
In addition to cardiovascular risks, Voltaren Gel carries an FDA black box warning for serious gastrointestinal (GI) adverse events, including bleeding, ulceration, and perforation of the stomach or intestines. These severe GI complications can be fatal and may occur at any time during use, often without preceding warning symptoms such as mild stomach ache or indigestion.
The risk of GI bleeding is heightened in certain populations. Elderly patients are at greater susceptibility to these adverse events. Patients with a prior history of peptic ulcer disease or previous gastrointestinal bleeding face a significantly elevated risk-more than ten times greater than those without such histories-who use NSAIDs like diclofenac. The risk also tends to increase with longer duration of use and higher cumulative doses.
Recognizing the signs of GI bleeding is crucial for patient safety. Warning indicators include feeling faint or lightheaded, passing bloody or black tarry stools (melena), coughing up blood, vomiting material that resembles coffee grounds, and experiencing persistent stomach pain that does not resolve. While topical application reduces systemic exposure compared to oral tablets, it does not eliminate the risk of GI injury. Any symptom suggestive of internal bleeding requires immediate medical attention and discontinuation of the medication.
Liver toxicity signs and monitoring
Diclofenac sodium, including its topical formulation, can cause liver injury ranging from mild enzyme elevations to severe hepatotoxicity, including liver necrosis, fulminant hepatitis with jaundice, and liver failure. In clinical studies involving thousands of diclofenac-treated patients, meaningful elevations in liver enzymes (more than three times the upper limit of normal) occurred in approximately 2% of participants. In larger open-label trials, about 4% of patients developed significant ALT and/or AST elevations, with roughly 1% experiencing marked elevations (more than eight times the upper limit).
Postmarketing surveillance has documented rare but serious cases of severe hepatic reactions that resulted in fatalities or required liver transplantation. A particularly dangerous aspect of diclofenac-induced liver injury is that severe hepatotoxicity may develop without a prodrome of distinguishing symptoms; users might not feel “sick” before experiencing significant liver damage.
Warning signs of liver toxicity include nausea, fatigue, lethargy, diarrhea, itching (pruritus), jaundice (yellowing of the skin or eyes), right upper quadrant abdominal tenderness, dark urine, and clay-colored stools. Because severe reactions can occur at any time, periodic monitoring of liver transaminases is recommended within 4 to 8 weeks after initiating long-term therapy. If liver injury is suspected based on symptoms or test results, diclofenac sodium should be discontinued immediately.
Kidney problems and fluid retention
NSAIDs, including topical diclofenac gel, can affect kidney function and fluid balance. Long-term administration of NSAIDs has been associated with renal papillary necrosis and other forms of renal injury. The risk of kidney damage is not zero for topical users; it remains highest in specific vulnerable populations. Patients at greatest risk include the elderly, those with pre-existing impaired renal function, heart failure, or liver dysfunction. Individuals taking diuretics (water pills) or ACE inhibitors are at increased risk because NSAIDs can interfere with the mechanisms these drugs rely on for kidney protection.
Voltaren Gel may also cause fluid retention and edema in some patients. This occurs because NSAIDs can reduce blood flow to the kidneys, altering how the body handles salt and water. Warning signs of fluid retention include noticeable swelling of the ankles, feet, or hands; sudden weight gain due to water accumulation; a decrease in the amount of urine produced; and shortness of breath caused by fluid buildup in the lungs.
For patients with advanced renal disease, treatment with Voltaren Gel is not recommended. If a user experiences signs of worsening kidney function or significant edema, particularly if they have underlying heart or kidney conditions, they should seek medical evaluation promptly. Fluid retention can exacerbate existing heart failure, making early recognition critical.
Allergic reactions and severe skin reactions
Voltaren Gel poses a risk of severe allergic reactions and life-threatening skin conditions. The medication is contraindicated in patients who have experienced asthma, urticaria (hives), or other allergic-type reactions after taking aspirin or other NSAIDs. These individuals are at high risk for severe, rarely fatal, anaphylactic-like reactions even when using the topical form. Anaphylactoid reactions can also occur in patients with no prior history of NSAID exposure.
Beyond immediate allergic responses, NSAIDs including Voltaren Gel can cause serious, potentially fatal skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN). These severe skin conditions can develop without warning and progress rapidly.
Signs of a serious allergic or skin reaction include hives, sneezing, runny or stuffy nose, wheezing, trouble breathing, and swelling of the face or throat. Skin-specific warnings involve fever accompanied by a rash, a red or purple skin rash that progresses to blisters or peeling skin, redness or swelling of the eyes, and body aches with fever and swollen lymph nodes. Any unexpected rash or sign of an allergic response should prompt immediate discontinuation of the gel and medical consultation. In cases of throat swelling or difficulty breathing, emergency care is required.
Who should avoid Voltaren Gel or consult a doctor first
Certain individuals should not use Voltaren Gel under any circumstances, while others must consult a healthcare provider before starting treatment to weigh risks against benefits. Absolute contraindications include known hypersensitivity to diclofenac, a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, and the peri-operative period surrounding coronary artery bypass graft (CABG) surgery.
Medical consultation is strongly recommended for patients with pre-existing conditions that increase susceptibility to serious side effects. These conditions include heart disease, high blood pressure, high cholesterol, diabetes, smoking habits, a history of heart attack, stroke, or blood clots, and a history of stomach ulcers or gastrointestinal bleeding. Asthma, liver disease, kidney disease, and fluid retention are also critical factors requiring prior medical evaluation.
Pregnancy is another major consideration. Voltaren Gel should be avoided in late pregnancy because NSAIDs may cause premature closure of the ductus arteriosus, a vital blood vessel in the fetus. Use is especially important to avoid at 20 weeks gestation or later unless specifically directed by a doctor, as it may cause problems in the unborn child or complications during delivery. Safety and effectiveness in pediatric patients under 18 years of age have not been established, so children should consult a doctor before use. Elderly patients generally face higher risks for severe side effects and should be monitored closely if therapy is necessary.
Drug interactions that increase side effect risk
Voltaren Gel can interact with other medications, potentially increasing the risk of serious adverse events. The most critical interactions involve bleeding risk. Combining Voltaren Gel with anticoagulants such as warfarin significantly increases the likelihood of bruising and gastrointestinal bleeding. The effects of anticoagulants and NSAIDs on GI bleeding are synergistic, meaning the combined risk is greater than either drug alone. Concurrent use with selective serotonin reuptake inhibitors (SSRIs like citalopram or fluoxetine) or serotonin-norepinephrine reuptake inhibitors (SNRIs) also elevates bleeding risk.
Users should avoid concomitant administration of Voltaren Gel with other oral NSAIDs or aspirin, as this increases the total systemic exposure to NSAIDs and amplifies adverse effects. The medication is not designed to be used simultaneously with other topical products on the same skin site; combining it with sunscreens, cosmetics, lotions, moisturizers, or insect repellants has not been tested and could increase local irritation or absorption unpredictably.
Other significant drug interactions involve kidney function and blood pressure regulation. NSAIDs may diminish the antihypertensive effect of ACE inhibitors and reduce the diuretic (natriuretic) effect of furosemide or thiazides, which can lead to signs of renal failure or reduced efficacy of these medications. Diclofenac may enhance the toxicity of methotrexate, increase nephrotoxicity when used with cyclosporine, and alter lithium levels by reducing its renal clearance. Caution and close monitoring are required when Voltaren Gel is used alongside these agents.
What to do if side effects occur and when to seek emergency care
If side effects occur while using Voltaren Gel, the appropriate response depends on the severity and type of symptom. For common, mild application site reactions such as slight redness or itching, users may try washing the area gently with soap and water and allowing the skin to rest before resuming use. Any persistent, worsening, or severe skin reaction warrants discontinuation and medical consultation.
Emergency care must be sought immediately if symptoms suggest a life-threatening condition. These include signs of a heart attack or stroke (chest pain spreading to the jaw/shoulder, sudden numbness, slurred speech, shortness of breath), signs of severe GI bleeding (vomiting blood, black tarry stools, feeling faint), signs of severe liver injury (jaundice, dark urine, persistent nausea), signs of kidney failure (decreased urination, significant swelling), or signs of a severe allergic reaction (difficulty breathing, swelling of the face/throat, widespread blistering rash).
For non-emergency but concerning symptoms-such as an unexpected rash, mild jaundice, persistent swelling, or decreased urine output-users should contact their healthcare provider promptly for advice. Do not stop long-term medication abruptly without medical guidance if it has been prescribed for a chronic condition, but do discontinue use immediately if emergency warning signs appear. Users are encouraged to report all side effects to their healthcare provider and can also report adverse events to the FDA MedWatch program. Using the lowest effective dose for the shortest duration necessary is the recommended strategy to minimize the risk of both local and systemic side effects.